Abstract:Background and objective: The therapeutic effects of chemotherapy for malignant neoplasms are still unsatisfactory. This study was to evaluate the chemosensitivity of colorectal cancer tissues to therapeutic agents using histoculture drug response assay (HDRA), and explore the correlation of chemosensitivity to the expression levels of multidrug resistance (MDR) genes and proteins. Methods: Twenty-two specimens of colorectal cancer were collected. The inhibition rates of single agents, including epirubicin, cisplatin (DDP), oxaliplatin, 5-FU, taxetere, irinotecan, and combinations of these agents, including 5-FU+epirubicin+DDP, 5-FU+irinotecan, 5-FU+oxaliplatin, 5-FU+taxetere+ DDP on colorectal cancer tissues were evaluated by HDRA. The agent whose inhibition rate was greater than 30% was considered sensitive, and the sensitivity was calculated. mRNA and protein levels of MDR genes and proteins in colorectal cancer tissues were measured by RT-PCR and immunohistochemistry. Results: Among the single agents, the inhibition rate of oxaliplatin (17.5%) and sensitivity of cancer tissues to 5-FU (36.4%) were the highest. In the combination groups of agents, the inhibition rate of 5-FU+ oxaliplatin (54.1%), and sensitivity of cancer tissues to 5-FU+epirubicin+DDP (71.4%) and to 5-FU+taxetere+DDP (71.4%) were the highest. The inhibition rates of and sensitivity of cancer tissues to combined agents were higher than those of single agents (P<0.05). Expressions of MDR1, multidrug resistance protein-1 (MRP1), ABC-binding cassette transporter superfamily-G-2 (ABCG2) mRNA were detected in 88.9%, 55.6% and 55.6% of specimens respectively; while those of MDR1, MRP1 and ABCG2 proteins were detected in 55.6%, 33.3%, and 50.0% of specimens respectively. Expressions of mRNA and proteins had no correlation in MDR1, MRP1 and ABCG2 (P>0.05). High expression of ABCG2 protein was correlated to the resistance of colorectal cancer cells to epirubicin (P<0.05). Conclusions: Expressions of MDR proteins are correlated to chemosensitivity of colorectal cancer to some extents. By combining HDRA with measurement of MDR genes and proteins, chemosensitivity of individual tumors may be predicted to guide selection of effective chemotherapeutic agents.

Relationship between Survivin,CTNNB1,hTERT mRNA expression and chemosensitivity of gastric cancer

Chemoresponse To Docetaxel Correlates With Expression Of The Survivin Splicing Variants In Patients With Gastric Cancer

The Relationships Between the Chemosensitivity of Human Gastric Cancer to Paclitaxel and the Expressions of Class III Β-Tubulin, MAPT, and Survivin

[Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer]

CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer.

Relationship Between Survivin Expression in Breast Cancer and the Efficacy of Different Neoadjuvant Chemotherapy Regimens

Effect of single nucleotide polymorphism of XRCC1 gene on the sensitivity of capecitabine combined with oxaliplatin as first line chemotherapy in gastric cancer patients

A Novel Model Including Cxcr4 And Cdk6 As Potential Predictive Marker For Docetaxel (Doc) Sensitivity In Gastric Cancer (Gc)

[Relationship Between Survivin Expression and Chemosensitivity of Human Lung Cancer Cells].

Relationship Between Plasma BRCA1 Mrna Expression and Sensitivity to Docetaxel and Cisplatin in Gastric Cancer.

A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer

The Correlation Between in Vitro Chemosensitvity Test and Expression of Multidrug Resistant 1 and Multidrug Resistance-Associated Proteins in Gastric Cancer

Ercc1 Mrna Expression And Xrcc1 Polymorphism As Predictive Factors For Overall Survival In Gastric Cancer Patients Receiving Platinum Based Chemotherapy

Significance Of Multidrug Resistance Gene-Related Proteins In The Postoperative Chemotherapy Of Gastric Cancer

[Association Between Genetic Polymorphisms of ERCC1, XRCC1, GSTP1 and Survival of Advanced Gastric Cancer Patients Treated with Oxaliplatin/5-Fu-based Chemotherapy].

[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues]

Relationship Between Mrna Expression of BRCA1 and Β-Tubulin III in Malignant Effusions and Ex Vivo Chemosenstitivity to Docetaxel

[Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer].

The relation between the chemotherapeutic efficacy and p53, P-glycoprotein and survival time in patients with gastric cancer

Polymorphisms of ERCC1, XRCC1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer

Gene Signature in Plasma and Tumor to Predict Irinotecan Chemosensitivity in Gastric Cancer.